#USA #Needham #Perceptive Discovery #Astatine-211 #Atley C100

Strategic Collaboration Between Atley Solutions and Perceptive Discovery

On January 23, 2026, Atley Solutions and Perceptive Discovery announced a pivotal partnership focused on the development of radiopharmaceuticals utilizing astatine-211 (At-211). This collaboration was underscored by the sale of two Atley C100 modules, which are the cornerstone of this initiative aimed at enhancing drug discovery and development capabilities in targeted alpha therapy. These advanced modules will enable precision oncology advancements utilizing the promising radionuclide At-211.

Pioneering Installations in the US and UK

The first Atley C100 module will be housed in the laboratories of Perceptive Discovery located in Needham, Massachusetts. Impressively, this installation marks the inaugural deployment of the Atley technology in a commercial contract research organization (CRO) within the United States. The second C100 module will take its place at the Queen Mary University of London, representing the UK’s first-ever installation of this innovative technology.

A Shared Vision for Next-Generation Therapies

The overarching goal of the partnership between Atley and Perceptive Discovery is to foster a robust infrastructure for the development of At-211 radiopharmaceuticals. The companies plan to combine their strengths, including advanced technological capabilities and extensive expertise, to speed up the process of discovering and developing new therapeutic candidates. The Atley C100, noted for its automation and efficiency, facilitates consistent and large-scale production while ensuring high standards of safety for operators.

This partnership intends to establish a strong foundation for preclinical evaluations, enabling scalable platforms tailored for research initiatives to clinical manufacturing. This enhancement of At-211 capabilities is seen as a milestone for both companies and will substantially benefit researchers and clients by improving access to cutting-edge cancer therapy technologies.

Enhancing Global Access to Radiopharmaceuticals

The alliance looks to create significant advancements in the targeted alpha therapy landscape. By deploying these Atley C100 modules in two prestigious environments in the US and UK, Perceptive Discovery is uniquely positioned to provide clients with tailored solutions for their therapeutic needs. Not only will these installations facilitate seamless production lines for innovative drugs, but they also promise to elevate the standard of preclinical and clinical research in the field of oncology.

As expressed by Ben Murphy, CEO of Perceptive Discovery, "At-211 is among the most promising radionuclides for targeted radionuclide therapy. Our collaboration will harness the innovative technologies of Atley alongside our leading capabilities to expedite the progression of future radiopharmaceutical products."

Milton Lönnroth, CEO of Atley Solutions, highlighted the monumental significance of this partnership: "Equipping Perceptive Discovery with the Atley C100 will empower joint efforts to develop At-211-based therapies more swiftly and effectively. This collaboration sets the stage for a transformative era in targeted therapy development."

About Atley Solutions

Atley Solutions stands at the forefront of developing commercial products and services tailored to the needs of At-211 radiopharmaceuticals. Recognized for its groundbreaking Atley C100 technology— the only automated solution specifically for At-211— the company addresses critical issues related to radionuclide production and scalability.

About Perceptive Discovery

Perceptive Discovery specializes in delivering advanced preclinical and translational research services that meld scientific innovation with clinical success for biotech and pharmaceutical entities. Equipped with comprehensive knowledge in areas such as radiochemistry and oncology models, they provide high-quality, actionable data to propel drug development forward.

With this strategic partnership, Atley Solutions and Perceptive Discovery aim not only to push the boundaries of radiopharmaceutical development but also to redefine the landscape of precision oncology, making strides that are set to alter the way we approach cancer treatment.